ID   FA34
AC   CVCL_IU78
DR   Cosmic; 2559131
DR   Wikidata; Q54833206
RX   PubMed=25653542;
CC   Doubling time: ~34 hours (PubMed=25653542).
CC   Sequence variation: Gene fusion; HGNC; HGNC:427; ALK + HGNC; HGNC:1316; EML4; Name(s)=EML4-ALK; Note=E6A20 v2 fusion (PubMed=25653542).
CC   Donor information: Established from a patient treated prior to cell line establishment with paclitaxel, pemetrexed, cisplatinum and erlotinib (PubMed=25653542).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 27-11-25; Version: 6
//
RX   PubMed=25653542; DOI=10.2147/OTT.S71242; PMCID=PMC4303463;
RA   Lam, David Chi-Leung
RA   Luo, Susan Y.
RA   Deng, Wen
RA   Kwan, Johnny Sheung-Him
RA   Rodriguez-Canales, Jaime
RA   Cheung, Annie Lai-Man
RA   Cheng, Grace H.-W.
RA   Lin, Chi-Ho
RA   Wistuba, Ignacio Ivan
RA   Sham, Pak Chung
RA   Wan, Thomas Shek-Kong
RA   Tsao, George Sai-Wah
RT   "Oncogenic mutation profiling in new lung cancer and mesothelioma cell
RT   lines.";
RL   Onco Targets Ther. 8:195-209(2015).
//